{
    "nct_id": "NCT04214288",
    "official_title": "SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer",
    "inclusion_criteria": "* Post-menopausal female patients aged at least 18 years.\n* Metastatic or loco-regionally recurrent ER-positive HER2-negative adenocarcinoma of the breast.\n* Radiological or other objective evidence of progression on or after the last systemic therapy prior to starting study treatment.\n* Patients must have at least 1 lesion, not previously irradiated, that can be measured accurately at baseline as â‰¥10 mm in the longest diameter or in absence of measurable disease as defined above, at least 1 lytic or mixed (lytic+sclerotic) bone lesion.\n* Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) performance status 0 to 1.\n* Prior endocrine therapy as follows:\n\n  1. Recurrence or progression on at least one line of endocrine therapy\n  2. No more than 1 line of endocrine therapy for advanced disease\n  3. No more than 1 line of chemotherapy for advanced disease\n  4. Prior treatment with CDK4/6 inhibitors is permitted\n  5. No prior treatment with fulvestrant, oral selective oestrogen receptor degrader (SERD), or related therapies\n* Inclusion criterion for the paired tumour biopsy research subgroup:\n\nWashout from prior tamoxifen: 4 months to elapse from last tamoxifen dose to pre-dose on-study biopsy.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
    "exclusion_criteria": "Intervention with any of the following:\n\n* Any cytotoxic chemotherapy, investigational agents or other anti-cancer drugs for the treatment of breast cancer from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.\n* Use of systemic oestrogen-containing hormone replacement therapy within 6 months prior to the first dose of study treatment.\n* Medications or herbal supplements known to be strong inhibitors/inducers of cytochrome P450 3A4/5 and sensitive CYP2B6 substrates, and drugs which are substrates of CYP2C9 and/or CYP2C19 which have a narrow therapeutic index or inability to stop use within the washout period prior to receiving the first dose of study treatment.\n* Drugs that are known to prolong QT and have a known risk of torsades de pointes.\n* The following cardiovascular criteria: QTcF >470 ms, resting heart rate <45 bpm, clinically significant abnormalities of resting electrocardiogram, uncontrolled hypertension, symptomatic hypotension, factors that increase the risk for QTc prolongation, left ventricular ejection fraction <50%.\n* Radiotherapy with a limited field of radiation for palliation within 1 week of dosing, or to > 30% of bone marrow or a wide field within 4 weeks of dosing.\n* Major surgical procedure or significant traumatic injury.\n* Presence of life-threatening metastatic visceral disease or uncontrolled central nervous system metastatic disease.\n* Inadequate bone marrow reserve or organ function.\n* Refractory nausea and vomiting, uncontrolled chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9833.\n* History of hypersensitivity to active or inactive excipients of AZD9833 or fulvestrant.\n* Previous randomisation in the present study.\n* Women of childbearing potential.",
    "miscellaneous_criteria": ""
}